Top

Published in:

01-09-2008 | Review

Extracellular ATP and Cancer—An Overview with Special Reference to P2 Purinergic Receptors

Authors: Tamás Deli, László Csernoch

Published in: Pathology & Oncology Research | Issue 3/2008

Abstract

Purinergic signal transduction mechanisms have been appreciated as a complex intercellular signalling network that plays an important regulatory role in both short- and long-term processes in practically every living cell. One of the most intriguing aspects of the field is the participation of ATP and other purine nucleotides in the determination of cell fate and the way they direct cells towards proliferation, differentiation or apoptosis, thereby possibly taking part in promoting or preventing malignant transformation. In this review, following a very brief introduction to the historical aspects of purinergic signalling and a concise overview of the structure of and signal transduction pathways coupled to P2 purinergic receptors, the current theories concerning the possible ways how extracellular ATP can alter the function of tumour cells and the effectiveness of anticancer therapies are discussed, including pharmacological, nutritional, vasoactive and ‘anti-antioxidant’ actions of the nucleotide. The effects of ATP on animals inoculated with human tumours and on patients with cancer are looked over next, and then an overview of the literature regarding the expression and presumed functions of P2 purinoceptors on tumour cells in vitro is presented, sorted out according to the relevant special clinical fields. The article is closed by reviewing the latest developments in the diagnostic use of P2 purinergic receptors as tumour markers and prognostic factors, while discussing some of the difficulties and pitfalls of the therapeutic use of ATP analogues.

Drury AN, Szent-Györgyi A (1929) The physiological activity of adenine compounds with special reference to their action upon the mammalian heart. J Physiol 68:213–237PubMed

Holton P (1959) The liberation of adenosine triphosphate on antidromic stimulation of sensory nerves. J Physiol (Lond) 145:494–504

Martinson J, Muren A (1963) Excitatory and inhibitory effects of vagus stimulation on gastric motility in the cat. Acta Physiol Scand 57:309–316CrossRef

Burnstock G (1972) Purinergic nerves. Pharmacol Rev 24:509–581PubMed

Burnstock G (1978) A basis for distinguishing two types of purinergic receptor. In: Straub RW and Bolis L (eds) Cell membrane receptors for drugs and hormones: a multidisciplinary approach. Raven, New York, pp 107–118

Burnstock G, Kennedy C (1985) Is there a basis for distinguishing two types of P₂-purinoceptor? Gen Pharmacol 16:433–440PubMed

Lazarowski E (2006) Regulated release of nucleotides and UDP sugars from astrocytoma cells. Novartis Found Symp 276:73–84 discussion 84–90, 107–12, 275–81CrossRefPubMed

Selzner N, Selzner M, Graf R, Ungethuem U, Fitz JG, Clavien PA (2004) Water induces autocrine stimulation of tumor cell killing through ATP release and P2 receptor binding. Cell Death Differ Suppl 2:S172–180CrossRef

Mazurek S, Boschek CB, Eigenbrodt E (1997) The role of phosphometabolites in cell proliferation, energy metabolism, and tumor therapy. J Bioenerg Biomembranes 29(4):315–330CrossRef

10.

Zimmermann H (2001) Ectonucleotidases: some recent developments and a note on nomenclature. Drug Dev Res 52:44–56CrossRef

11.

Bavaresco L, Bernardi A, Braganhol E, Wink MR, Battastini AM (2007) Dexamethasone inhibits proliferation and stimulates ecto-5′-nucleotidase/CD73 activity in C6 rat glioma cell line. J Neurooncol 84(1):1–8CrossRefPubMed

12.

Kunzli BM, Berberat PO, Giese T, Csizmadia E, Kaczmarek E, Baker C, Halaceli I, Buchler MW, Friess H, Robson SC (2007) Upregulation of CD39/NTPDases and P2 receptors in human pancreatic disease. Am J Physiol Gastrointest Liver Physiol 292(1):G223–G230CrossRefPubMed

13.

Jackson SW, Hoshi T, Wu Y, Sun X, Enjyoji K, Csizmadia E, Sundberg C, Robson SC (2007) Disordered purinergic signaling inhibits pathological angiogenesis in cd39/Entpd1-null mice. Am J Pathol 171(4):1395–1404CrossRefPubMed

14.

Merighi S, Mirandola P, Varani K, Gessi S, Leung E, Baraldi PG, Tabrizi MA, Borea PA (2003) A glance at adenosine receptors: novel target for antitumor therapy. Pharmacol Ther 100(1):31–48CrossRefPubMed

15.

North RA (2002) Molecular physiology of P2X receptors. Physiol Rev 82(4):1013–1067PubMed

16.

Bean BP (1992) Pharmacology and electrophysiology of ATP-activated ion channels. Trends Pharmacol Sci 13(3):87–90CrossRefPubMed

17.

Egan TM, Samways DS, Li Z (2006) Biophysics of P2X receptors. Pflügers Arch 452(5):501–512CrossRefPubMed

18.

Thomas SA, Hume RI (1990) Permeation of both cations and anions through a single class of ATP-activated ion channels in developing chick skeletal muscle. J Gen Physiol 95:569–590CrossRefPubMed

19.

Kim M, Jiang LH, Wilson HL, North RA, Surprenant A (2001) Proteomic and functional evidence for a P2X7 receptor signalling complex. EMBO J 20(22):6347–6358CrossRefPubMed

20.

Kahlenberg JM, Dubyak GR (2004) Mechanisms of caspase-1 activation by P2X7 receptor-mediated K+ release. Am J Physiol Cell Physiol 286(5):C1100–C1108CrossRefPubMed

21.

Bulanova E, Budagian V, Orinska Z, Hein M, Petersen F, Thon L, Adam D, Bulfone-Paus S (2005) Extracellular ATP induces cytokine expression and apoptosis through P2X7 receptor in murine mast cells. J Immunol 174(7):3880–3890PubMed

22.

Wang Q, Wang L, Feng YH, Li X, Zeng R, Gorodeski GI (2004) P2X7 receptor-mediated apoptosis of human cervical epithelial cells. Am J Physiol Cell Physiol 287(5):C1349–C1358CrossRefPubMed

23.

Ferrari D, Chiozzi P, Falzoni S, Dal Susino M, Melchiorri L, Baricordi OR, Di Virgilio F (1997) Extracellular ATP triggers IL-1 beta release by activating the purinergic P2Z receptor of human macrophages. J Immunol 159(3):1451–1458PubMed

24.

Verhoef PA, Estacion M, Schilling W, Dubyak GR (2003) P2X7 receptor-dependent blebbing and the activation of Rho-effector kinases, caspases, and IL-1 beta release. J Immunol 170(11):5728–5738PubMed

25.

Chiozzi P, Murgia M, Falzoni S, Ferrari D, Di Virgilio F (1996) Role of the purinergic P2Z receptor in spontaneous cell death in J774 macrophage cultures. Biochem Biophys Res Commun 218(1):176–181CrossRefPubMed

26.

Ralevic V, Burnstock G (1998) Receptors for purines and pyrimidines. Pharmacol Rev 50(3):413–492PubMed

27.

Burnstock G (2006) Purinergic signalling. Br J Pharmacol 147(Suppl 1):S172–S181CrossRefPubMed

28.

Burnstock G (2006) Purinergic signalling—an overview. Novartis Found Symp 276:26–48 discussion 48–57, 275–81CrossRefPubMed

29.

Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D, Conley PB (2001) Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409:202–207CrossRefPubMed

30.

Marteau F, Le Poul E, Communi D, Communi D, Labouret C, Savi P, Boeynaems J-M, Suarez Gonzalez N (2003) Pharmacological characterization of the human P2Y₁₃ receptor. Mol Pharmacol 64:104–112CrossRefPubMed

31.

Szigeti GP, Szappanos H, Deli T, Cseri J, Kovács L, Csernoch L (2007) Differentiation-dependent alterations in the extracellular ATP-evoked calcium fluxes of cultured skeletal muscle cells from mice. Pflugers Arch 453(4):509–518CrossRefPubMed

32.

Deli T, Szappanos H, Szigeti GP, Cseri J, Kovács L, Csernoch L (2007) Contribution from P2X and P2Y purinoreceptors to ATP-evoked changes in intracellular calcium concentration on cultured myotubes. Pflugers Arch 453(4):519–529CrossRefPubMed

33.

Burnstock G (2006) Pathophysiology and therapeutic potential of purinergic signaling. Pharmacol Rev 58(1):58–86CrossRefPubMed

34.

Rapaport E (1983) Treatment of human tumor cells with ADP or ATP yields arrest of growth in the S phase of the cell cycle. J Cell Physiol 114(3):279–283CrossRefPubMed

35.

Rapaport E, Fishman RF, Gercel C (1983) Growth inhibition of human tumor cells in soft-agar cultures by treatment with low levels of adenosine 5′-triphosphate. Cancer Res 43(9):4402–4406PubMed

36.

Rapaport E (1988) Experimental cancer therapy in mice by adenine nucleotides. Eur J Cancer Clin Oncol 24(9):1491–1497CrossRefPubMed

37.

Wiley JS, Dao-Ung LP, Gu BJ, Sluyter R, Shemon AN, Li C, Taper J, Gallo J, Manoharan A (2002) A loss-of-function polymorphic mutation in the cytolytic P2X7 receptor gene and chronic lymphocytic leukaemia: a molecular study. Lancet 359(9312):1114–1119CrossRefPubMed

38.

Zhang XJ, Zheng GG, Ma XT, Yang YH, Li G, Rao Q, Nie K, Wu KF (2004) Expression of P2X7 in human hematopoietic cell lines and leukemia patients. Leuk Res 28(12):1313–1322CrossRefPubMed

39.

Deli T, Varga N, Adam A, Kenessey I, Raso E, Puskas LG, Tovari J, Fodor J, Feher M, Szigeti GP, Csernoch L, Timar J (2007) Functional genomics of calcium channels in human melanoma cells. Int J Cancer 121(1):55–65CrossRefPubMed

40.

Feng YH, Li X, Zeng R, Gorodeski GI (2006) Endogenously expressed truncated P2X7 receptor lacking the C-terminus is preferentially upregulated in epithelial cancer cells and fails to mediate ligand-induced pore formation and apoptosis. Nucleosides Nucleotides Nucleic Acids 25(9–11):1271–1276CrossRefPubMed

41.

Krzeminski P, Misiewicz I, Pomorski P, Kasprzycka-Guttman T, Branska J (2007) Mitochondrial localization of P2Y1, P2Y2 and P2Y12 receptors in rat astrocytes and glioma C6 cells. Brain Res Bull 71(6):587–592CrossRefPubMed

42.

Rapaport E, Fontaine J (1989) Anticancer activities of adenine nucleotides in mice are mediated through expansion of erythrocyte ATP pools. Proc Natl Acad Sci USA 86(5):1662–1666CrossRefPubMed

43.

Rapaport E, Fontaine J (1989) Generation of extracellular ATP in blood and its mediated inhibition of host weight loss in tumor-bearing mice. Biochem Pharmacol 38(23):4261–4266CrossRefPubMed

44.

Ristow M (2006) Oxidative metabolism in cancer growth. Curr Opin Clin Nutr Metab Care 9(4):339–345CrossRefPubMed

45.

Baba T, Fukui M, Sakata S, Tashima T, Takeshita I, Nakamura T, Inoue T (1989) Selective enhancement of intratumoural blood flow in malignant gliomas: experimental study in rats by intracarotid administration of adenosine or adenosine triphosphate. Acta Neurochir (Wien) 101(1–2):66–74CrossRef

46.

Estrela JM, Obrador E, Navarro J, Lasso De la Vega MC, Pellicer JA (1995) Elimination of Ehrlich tumours by ATP-induced growth inhibition, glutathione depletion and X-rays. Nat Med 1(1):84–88CrossRefPubMed

47.

Obrador E, Navarro J, Mompo J, Asensi M, Pellicer JA, Estrela JM (1997) Glutathione and the rate of cellular proliferation determine tumour cell sensitivity to tumour necrosis factor in vivo. Biochem J 325(Pt 1):183–189PubMed

48.

Shabbir M, Thompson C, Jarmulowiczc M, Mikhailidis D, Burnstock G (2008) Effect of extracellular ATP on the growth of hormone-refractory prostate cancer in vivo. BJU Int 102(1):108–112CrossRefPubMed

49.

Shabbir M, Ryten M, Thompson C, Mikhailidis D, Burnstock G (2008) Purinergic receptor-mediated effects of ATP in high-grade bladder cancer. BJU Int 101(1):106–112PubMed

50.

Abraham EH, Salikhova AY, Rapaport E (2003) ATP in the treatment of advanced cancer. Curr Top Membr 54:415–452CrossRef

51.

Haskell CM, Wong M, Williams A, Lee LY (1996) Phase I trial of extracellular adenosine 5′-triphosphate in patients with advanced cancer. Med Pediatr Oncol 27(3):165–173CrossRefPubMed

52.

Haskell CM, Mendoza E, Pisters KM, Fossella FV, Figlin RA (1998) Phase II study of intravenous adenosine 5′-triphosphate in patients with previously untreated stage IIIB and stage IV non-small cell lung cancer. Invest New Drugs 16(1):81–85CrossRefPubMed

53.

Agteresch HJ, Dagnelie PC, van der Gaast A, Stijnen T, Wilson JH (2000) Randomized clinical trial of adenosine 5′-triphosphate in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 92(4):321–328CrossRefPubMed

54.

Agteresch HJ, Leij-Halfwerk S, Van Den Berg JW, Hordijk-Luijk CH, Wilson JH, Dagnelie PC (2000) Effects of ATP infusion on glucose turnover and gluconeogenesis in patients with advanced non-small-cell lung cancer. Clin Sci (Lond) 98(6):689–695CrossRef

55.

Leij-Halfwerk S, Agteresch HJ, Sijens PE, Dagnelie PC (2002) Adenosine triphosphate infusion increases liver energy status in advanced lung cancer patients: an in vivo 31P magnetic resonance spectroscopy study. Hepatology 35(2):421–424CrossRefPubMed

56.

Agteresch HJ, Burgers SA, van der Gaast A, Wilson JH, Dagnelie PC (2003) Randomized clinical trial of adenosine 5′-triphosphate on tumor growth and survival in advanced lung cancer patients. Anticancer Drugs 14(8):639–644CrossRefPubMed

57.

Hatta Y, Takahashi M, Enomoto Y, Takahashi N, Sawada U, Horie T (2004) Adenosine triphosphate (ATP) enhances the antitumor effect of etoposide (VP16) in lung cancer cells. Oncol Rep 12:1139–1142PubMed

58.

Shabbir M, Thompson CS, Mikhailidis DP, Morgan RJ, Burnstock G (2004) Adenosine 5-triphosphate (ATP) increases the cytotoxic effect of mitomycin C in the treatment of high-grade bladder cancer. J Urol 171(Suppl 4):260

59.

Schafer R, Sedehizade F, Welte T, Reiser G (2003) ATP- and UTP-activated P2Y receptors differently regulate proliferation of human lung epithelial tumor cells. Am J Physiol Lung Cell Mol Physiol 285:L376–L385PubMed

60.

Shabbir M, Ryten M, Thompson C, Mikhailidis D, Burnstock G (2008) Characterization of calcium-independent purinergic receptor-mediated apoptosis in hormone-refractory prostate cancer. BJU Int 101(3):352–359CrossRefPubMed

61.

Slater M, Danieletto S, Barden JA (2005) Expression of the apoptotic calcium channel P2X7 in the glandular epithelium. J Mol Histol 36(3):159–165CrossRefPubMed

62.

Slater M, Danieletto S, Gidley-Baird A, Teh LC, Barden JA (2004) Early prostate cancer detected using expression of non-functional cytolytic P2X7 receptors. Histopathology 44(3):206–215CrossRefPubMed

63.

Li X, Zhou L, Feng YH, Abdul-Karim FW, Gorodeski GI (2006) The P2X7 receptor: a novel biomarker of uterine epithelial cancers. Cancer Epidemiol Biomarkers Prev 15(10):1906–1913CrossRefPubMed

64.

Czajkowski R, Lei L, Sabala P, Baranska J (2002) ADP-evoked phospholipase C stimulation and adenylyl cyclase inhibition in glioma C6 cells occur through two distinct nucleotide receptors, P2Y(1) and P2Y(12). FEBS Lett 513(2–3):179–183CrossRefPubMed

65.

Krzeminski P, Suplat D, Czajkowski R, Pomorski P, Baranska J (2007) Expression and functional characterization of P2Y1 and P2Y12 nucleotide receptors in long-term serum-deprived glioma C6 cells. FEBS J 274(8):1970–1982CrossRefPubMed

66.

Van Kolen K, Slegers H (2006) Atypical PKCzeta is involved in RhoA-dependent mitogenic signaling by the P2Y(12) receptor in C6 cells. FEBS J 273(8):1843–1854CrossRefPubMed

67.

Morrone FB, Jacques-Silva MC, Horn AP, Bernardi A, Schwartsmann G, Rodnight R, Lenz G (2003) Extracellular nucleotides and nucleosides induce proliferation and increase nucleoside transport in human glioma cell lines. J Neurooncol 64(3):211–218CrossRefPubMed

68.

Cavaliere F, Nestola V, Amadio S, D’Ambrosi N, Angelini DF, Sancesario G, Bernardi G, Volonte C (2005) The metabotropic P2Y4 receptor participates in the commitment to differentiation and cell death of human neuroblastoma SH-SY5Y cells. Neurobiol Dis 18(1):100–109CrossRefPubMed

69.

Lakshmi S, Joshi PG (2006) Activation of Src/kinase/phospholipase C/mitogen-activated protein kinase and induction of neurite expression by ATP, independent of nerve growth factor. Neuroscience 141(1):179–189CrossRefPubMed

70.

Raffaghello L, Chiozzi P, Falzoni S, Di Virgilio F, Pistoia V (2006) The P2X7 receptor sustains the growth of human neuroblastoma cells through a substance P-dependent mechanism. Cancer Res 66(2):907–914CrossRefPubMed

71.

Janssens R, Boeynaems JM (2001) Effects of extracellular nucleotides and nucleosides on prostate carcinoma cells. Br J Pharmacol 132(2):536–546CrossRefPubMed

72.

Calvert RC, Shabbir M, Thompson CS, Mikhailidis DP, Morgan RJ, Burnstock G (2004) Immunocytochemical and pharmacological characterisation of P2-purinoceptor-mediated cell growth and death in PC-3 hormone refractory prostate cancer cells. Anticancer Res 24(5A):2853–2859PubMed

73.

Chen L, He HY, Li HM, Zheng J, Heng WJ, You JF, Fang WG (2004) ERK1/2 and p38 pathways are required for P2Y receptor-mediated prostate cancer invasion. Cancer Lett 215(2):239–247CrossRefPubMed

74.

Katzur AC, Koshimizu T, Tomic M, Schultze-Mosgau A, Ortmann O, Stojilkovic SS (1999) Expression and responsiveness of P2Y2 receptors in human endometrial cancer cell lines. J Clin Endocrinol Metab 84(11):4085–4091CrossRefPubMed

75.

Schultze-Mosgau A, Katzur AC, Arora KK, Stojilkovic SS, Diedrich K, Ortmann O (2000) Characterization of calcium-mobilizing, purinergic P2Y(2) receptors in human ovarian cancer cells. Mol Hum Reprod 6(5):435–442CrossRefPubMed

76.

Choi KC, Tai CJ, Tzeng CR, Auersperg N, Leung PC (2003) Adenosine triphosphate activates mitogen-activated protein kinase in pre-neoplastic and neoplastic ovarian surface epithelial cells. Biol Reprod 68(1):309–315CrossRefPubMed

77.

Popper LD, Batra S (1993) Calcium mobilization and cell proliferation activated by extracellular ATP in human ovarian tumour cells. Cell Calcium 14(3):209–218CrossRefPubMed

78.

Vandewalle B, Hornez L, Revillion F, Lefebvre J (1994) Effect of extracellular ATP on breast tumor cell growth, implication of intracellular calcium. Cancer Lett 85(1):47–54CrossRefPubMed

79.

Dixon CJ, Bowler WB, Fleetwood P, Ginty AF, Gallagher JA, Carron JA (1997) Extracellular nucleotides stimulate proliferation in MCF-7 breast cancer cells via P2-purinoceptors. Br J Cancer 75(1):34–39PubMed

80.

Slater M, Danieletto S, Pooley M, Cheng Teh L, Gidley-Baird A, Barden JA (2004) Differentiation between cancerous and normal hyperplastic lobules in breast lesions. Breast Cancer Res Treat 83(1):1–10CrossRefPubMed

81.

Gow IF, Thomson J, Davidson J, Shennan DB (2005) The effect of a hyposmotic shock and purinergic agonists on K+(Rb+) efflux from cultured human breast cancer cells. Biochim Biophys Acta 1712(1):52–61CrossRefPubMed

82.

Maaser K, Hopfner M, Kap H, Sutter AP, Barthel B, von Lampe B, Zeitz M, Scherubl H (2002) Extracellular nucleotides inhibit growth of human oesophageal cancer cells via P2Y(2)-receptors. Br J Cancer 86(4):636–644CrossRefPubMed

83.

Wang MX, Ren LM (2006) Growth inhibitory effect and apoptosis induced by extracellular ATP and adenosine on human gastric carcinoma cells: involvement of intracellular uptake of adenosine. Acta Pharmacol Sin 27(8):1085–1092CrossRefPubMed

84.

Hopfner M, Lemmer K, Jansen A, Hanski C, Riecken EO, Gavish M, Mann B, Buhr H, Glassmeier G, Scherubl H (1998) Expression of functional P2-purinergic receptors in primary cultures of human colorectal carcinoma cells. Biochem Biophys Res Commun 251(3):811–817CrossRefPubMed

85.

Coutinho-Silva R, Stahl L, Cheung KK, de Campos NE, de Oliveira Souza C, Ojcius DM, Burnstock G (2005) P2X and P2Y purinergic receptors on human intestinal epithelial carcinoma cells: effects of extracellular nucleotides on apoptosis and cell proliferation. Am J Physiol Gastrointest Liver Physiol 288(5):G1024–G1035CrossRefPubMed

86.

Nylund G, Nordgren S, Delbro DS (2004) Expression of P2Y2 purinoceptors in MCG 101 murine sarcoma cells, and HT-29 human colon carcinoma cells. Auton Neurosci 112(1–2):69–79CrossRefPubMed

87.

Delbro DS, Nylund G, Nordgren S (2005) Demonstration of P2Y4 purinergic receptors in the HT-29 human colon cancer cell line. Auton Autacoid Pharmacol 25(4):163–166CrossRefPubMed

88.

Nylund G, Hultman L, Nordgren S, Delbro DS (2007) P2Y2- and P2Y4 purinergic receptors are over-expressed in human colon cancer. Auton Autacoid Pharmacol 27(2):79–84CrossRefPubMed

89.

Pines A, Perrone L, Bivi N, Romanello M, Damante G, Gulisano M, Kelley MR, Quadrifoglio F, Tell G (2005) Activation of APE1/Ref-1 is dependent on reactive oxygen species generated after purinergic receptor stimulation by ATP. Nucleic Acids Res 33(14):4379–4394CrossRefPubMed

90.

Pines A, Bivi N, Vascotto C, Romanello M, D’Ambrosio C, Scaloni A, Damante G, Morisi R, Filetti S, Ferretti E, Quadrifoglio F, Tell G (2006) Nucleotide receptors stimulation by extracellular ATP controls Hsp90 expression through APE1/Ref-1 in thyroid cancer cells: a novel tumorigenic pathway. J Cell Physiol 209(1):44–55CrossRefPubMed

91.

Solini A, Cuccato S, Ferrari D, Santini E, Gulinelli S, Callegari MG, Dardano A, Faviana P, Madec S, Di Virgilio F, Monzani F (2008) Increased P2X7 receptor expression and function in thyroid papillary cancer: a new potential marker of the disease? Endocrinology 149(1):389–396CrossRefPubMed

92.

Hatta Y, Aizawa S, Itoh T, Baba M, Horie T (1994) Cytotoxic effect of extracellular ATP on L1210 leukemic cells and normal hemopoietic stem cells. Leuk Res 18(8):637–641CrossRefPubMed

93.

Conigrave AD, van der Weyden L, Holt L, Jiang L, Wilson P, Christopherson RI, Morris MB (2000) Extracellular ATP-dependent suppression of proliferation and induction of differentiation of human HL-60 leukemia cells by distinct mechanisms. Biochem Pharmacol 60(11):1585–1591CrossRefPubMed

94.

Adinolfi E, Melchiorri L, Falzoni S, Chiozzi P, Morelli A, Tieghi A, Cuneo A, Castoldi G, Di Virgilio F, Baricordi OR (2002) P2X7 receptor expression in evolutive and indolent forms of chronic B lymphocytic leukemia. Blood 99(2):706–708CrossRefPubMed

95.

Bernardo AA, Pinto-Silva FE, Persechini PM, Coutinho-Silva R, Meyer-Fernandes JR, de Souza AL, Rumjanek VM (2006) Effect of extracellular ATP on the human leukaemic cell line K562 and its multidrug counterpart. Mol Cell Biochem 289(1–2):111–124CrossRefPubMed

96.

Yoon MJ, Lee HJ, Kim JH, Kim DK (2006) Extracellular ATP induces apoptotic signaling in human monocyte leukemic cells, HL-60 and F-36P. Arch Pharm Res 29(11):1032–1041CrossRefPubMed

97.

Shemon AN, Sluyter R, Wiley JS (2007) Rottlerin inhibits P2X(7) receptor-stimulated phospholipase D activity in chronic lymphocytic leukaemia B-lymphocytes. Immunol Cell Biol 85(1):68–72CrossRefPubMed

98.

Greig AV, Linge C, Healy V, Lim P, Clayton E, Rustin MH, McGrouther DA, Burnstock G (2003) Expression of purinergic receptors in non-melanoma skin cancers and their functional roles in A431 cells. J Invest Dermatol 121(2):315–327CrossRefPubMed

99.

White N, Ryten M, Clayton E, Butler P, Burnstock G (2005) P2Y purinergic receptors regulate the growth of human melanomas. Cancer Lett 224(1):81–91PubMed

100.

White N, Butler PE, Burnstock G (2005) Human melanomas express functional P2X(7) receptors. Cell Tissue Res 321(3):411–418CrossRefPubMed

Title: Extracellular ATP and Cancer—An Overview with Special Reference to P2 Purinergic Receptors
Authors: Tamás Deli
László Csernoch
Publication date: 01-09-2008
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 3/2008
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-008-9071-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2008

No Strong Association Between HER-2/neu Protein Overexpression and Gene Amplification in High-grade Invasive Urothelial Carcinomas

Signet-Ring Stromal Tumor of the Ovary: Report of a Case and Review of the Literature

Systemic Dissemination in Cancer of Unknown Primary is Independent of Mutational Inactivation of the KiSS-1 Metastasis-suppressor Gene

Alterations of the CD4+, CD8+ T Cell Subsets, Interleukins-1β, IL-10, IL-17, Tumor Necrosis Factor-α and Soluble Intercellular Adhesion Molecule-1 in Rheumatoid Arthritis and Osteoarthritis: Preliminary Observations

Osteopontin Expression Correlates with Angiogenesis and Survival in Malignant Astrocytoma

Bcl-2 Antisense Oligonucleotide Inhibits the Proliferation of Childhood Leukemia/lymphoma Cells of the B-cell Lineage

Keynote webinar | Spotlight on antibody–drug conjugates in cancer